We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Astellas Pharma Inc. (ALPMY - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Astellas Pharma Inc. is a member of our Medical group, which includes 923 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Astellas Pharma Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ALPMY's full-year earnings has moved 3.3% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that ALPMY has returned about 18.4% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -6.7% on a year-to-date basis. As we can see, Astellas Pharma Inc. is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is Cardinal Health (CAH - Free Report) . The stock is up 0.8% year-to-date.
Over the past three months, Cardinal Health's consensus EPS estimate for the current year has increased 4.4%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Astellas Pharma Inc. belongs to the Medical - Drugs industry, which includes 143 individual stocks and currently sits at #95 in the Zacks Industry Rank. Stocks in this group have lost about 4.9% so far this year, so ALPMY is performing better this group in terms of year-to-date returns.
On the other hand, Cardinal Health belongs to the Medical - Dental Supplies industry. This 15-stock industry is currently ranked #53. The industry has moved -2.7% year to date.
Investors with an interest in Medical stocks should continue to track Astellas Pharma Inc. and Cardinal Health. These stocks will be looking to continue their solid performance.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Astellas Pharma Inc. (ALPMY - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Astellas Pharma Inc. is a member of our Medical group, which includes 923 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Astellas Pharma Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ALPMY's full-year earnings has moved 3.3% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that ALPMY has returned about 18.4% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -6.7% on a year-to-date basis. As we can see, Astellas Pharma Inc. is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is Cardinal Health (CAH - Free Report) . The stock is up 0.8% year-to-date.
Over the past three months, Cardinal Health's consensus EPS estimate for the current year has increased 4.4%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Astellas Pharma Inc. belongs to the Medical - Drugs industry, which includes 143 individual stocks and currently sits at #95 in the Zacks Industry Rank. Stocks in this group have lost about 4.9% so far this year, so ALPMY is performing better this group in terms of year-to-date returns.
On the other hand, Cardinal Health belongs to the Medical - Dental Supplies industry. This 15-stock industry is currently ranked #53. The industry has moved -2.7% year to date.
Investors with an interest in Medical stocks should continue to track Astellas Pharma Inc. and Cardinal Health. These stocks will be looking to continue their solid performance.